GeneDx Holdings (WGS) Other Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Other Accumulated Expenses for 7 consecutive years, with $35.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 46.4% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $35.9 million (up 46.4% YoY), while the FY2025 annual figure was $46.9 million, up 128.6% from the prior year.
• Other Accumulated Expenses retreated to $35.9 million in Q1 2026 per WGS's latest filing, from $46.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $81.6 million in Q2 2022 and bottomed at $1.0 million in Q2 2023.
• Historically, Other Accumulated Expenses has averaged $28.8 million across 5 years, with a median of $23.4 million in 2022.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 98.77% — and 2024, when it surged 1386.44%.
• GeneDx Holdings' Other Accumulated Expenses stood at $49.7 million in 2022, then sank by 97.23% to $1.4 million in 2023, then soared by 1386.44% to $20.5 million in 2024, then jumped by 128.6% to $46.9 million in 2025, then slipped by 23.28% to $35.9 million in 2026.
• Business Quant data shows WGS's Other Accumulated Expenses at $35.9 million in Q1 2026, $46.9 million in Q4 2025, and $32.9 million in Q3 2025.